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Objective: To investigate the correlation between E670G polymorphism of proprotein
convertase subtilisin/kexin type 9 (PCSK9) gene and coronary heart disease (CHD), and
contrastively study the regional differences of E670G polymorphism of PCSK9 gene
between patients with CHD among the Han population in Hainan and three provinces in
the northeast of China (TPNC), providing scientiﬁc basis for prevention and treatment of
patients with CHD in different regions.
Methods: A total of 233 cases of patients with CHD were selected from the Han pop-
ulation in Hainan and TPNC as the experimental group (118 cases from Hainan, 115
cases from TPNC), and 239 cases with non-CHD were selected among the Han popu-
lation also in the two regions as control group (125 cases from Hainan, 114 cases from
TPNC). The triglyceride (TG), total cholesterol (TC), high density lipoprotein cholesterol
and low density lipoprotein cholesterol (LDL-C) levels of plasma were tested and PCR-
RFLP method was used to test the E670G polymorphism of PCSK9 gene. The statistical
software package SPSS 21.0 was used for the statistical analysis and P < 0.05 was
considered as statistically signiﬁcant.
Results: The levels of systolic pressure, diastolic blood pressure, fasting blood sugar,
TC, TG, and LDL-C of patients in CHD group were signiﬁcantly higher than those in
non-CHD group, while the high density lipoprotein cholesterol level was lower than that
in non-CHD group (P < 0.05). In CHD group, the frequencies of AG, GG genotypes of
PCSK9 gene and G allele were higher than those in non-CHD group (P < 0.05), and in
CHD group, the frequencies of AG, GG genotypes and G allele of patients both in Hainan
and TPNC were higher than those in control group (P < 0.05). Among the patients with
CHD, the frequencies of GG genotype and G allele of patients in Hainan were lower than
those in TPNC (P < 0.05), and in CHD group, the levels of TG, TC and LDL-C of GG
genotype were higher than those of AA genotype (P < 0.05). While in non-CHD group,
there were no signiﬁcant differences between the frequencies of GG genotype and G
allele of patients in Hainan and TPNC (P > 0.05).
Conclusions: There was a close correlation between the E670G polymorphism of
PCSK9 gene and CHD with serum lipid level. Among Han population in Hainan and
TPNC, the E670G polymorphism of PCSK9 gene of patients with CHD exhibited
regional differences.1. Introduction
The coronary heart disease (CHD) is a common heart disease
seriously threatening human health with increasing morbidityand mortality as the changes of social environment and people's
living habits. Many researches showed that the CHD is related to
various genetic factors, especially the genes involved in lipid
metabolism playing a signiﬁcant role in its occurrence and
development. The proprotein convertase subtilisin/kexin type 9
(PCSK9) is a newly discovered gene involving in autosomal
dominant hypercholesterolemia through a mechanism of that it
adjusts the low density cholesterol levels, thereby having an
effect on the risk of CHD occurrence [1,2]. Polymorphic site ofnder the CC BY-NC-ND license (http://
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As the discrepancies may exist among distinct regions or races,
the risk of CHD may also exhibit differences.
In the present study, the E670G polymorphism of PCSK9
gene in patients with CHD among Han population in Hainan and
three provinces in the northeast of China (TPNC) and the non-
CHD people were carried out to identify the correlation be-
tween E670G polymorphism and CHD, and to discuss whether
there was regional difference in E670G polymorphism among
distinct areas and its effects on the serum lipid metabolism.
2. Materials and methods
2.1. Study objects
A total of 233 cases of patients with CHD were selected from
the Han population in Hainan and TPNC as the observation
group (118 cases from Hainan, 115 cases from TPNC) with an
average age as (63.95 ± 12.35) years old. And 239 cases (non-
CHD) having the roughly same condition in gender, age and
period of resident, etc. were selected among the Han population
and the two regions as control group (125 cases from Hainan,
114 cases from TPNC) with an average age as (61.68 ± 13.07)
years old. Here, the study objects were the Han nationality.
2.1.1. Inclusion criteria
The diagnostic criteria for CHD were referred to the Coro-
nary Atherosclerotic Heart Disease Diagnosis Standard (WS
319-2010, Health industry standard of the People's Republic of
China).
2.1.2. Exclusion criteria
The non-Han population was excluded in this study. The
patients with acute or chronic infectious diseases, malignant
tumor, autoimmune disease, a family history of hyperlipidemia
or other diseases might inﬂuence the experiment results were not
considered as the study objects. CHD patients without sufﬁcient
basic information were also excluded to avoid inaccuracy of the
results.
2.2. Main reagents and instruments
In the present study, main reagents used in experiments were
DNA extraction kit (CWBIO), upstream and downstream
primers (Beijing SBS Corporation), 2×EcoTaq PCR SuperMix
(+dye) (CWBIO), agarose (Biowest), Ladder Marker (CWBIO),
RNase-Free Water (CWBIO), and restriction endonuclease
Eam1104I (Fermentas); the main instruments were Biometra
PCR (Biometra, Germany), electrophoresis apparatus (Tanon
EPS-300, Shanghai Tianneng Technology Co., LTD), nucleic
acid analyser (Eppendorf, Germany), fully automatic biochem-
ical analyser (Hitachi 7600, Japan), UV analysis tapping ma-
chine (UV-2000, Shanghai Tianneng Technology Co., LTD) and




A moderate amount of blood specimens of study objects were
collected for the extraction of genomic DNA and thedeterminations of serum lipid, blood glucose and other
biochemical indexes.
2.3.2. DNA preparation of human peripheral blood
The extraction of genomic DNA was conducted strictly
complied with the kit introduction. The outside diameter value
of DNA was tested approximately at 1.8 (A260 nm/A280 nm),
which showed the DNA purity was in accord with PCR requires.
2.3.3. PCR ampliﬁcation
To ﬁnd the polymorphic loci gene sequences of E670G of
PCSK9 gene in gene bank, and then the Primer was used for the
primer design. Sense primer was 50-CAC GGT TGT GTC CCA
AAT GG-30. Reverse primer was 50-GAG AGG GAC AAG
TCG GAA CC-30. The ampliﬁed fragment was 440 bp. The
PCR primer was synthesized by Beijing SBS Corporation.
The total volume of reactant was 50 mL. Among it, DNA
extraction was 10 mL, 2×EcoTaq PCR SuperMix was 13 mL, the
upstream and downstream primers were both 2 mL and the rest
23 mL was RNase-free water. These materials were blend and
then placed in PCR ampliﬁer for the ampliﬁcation reaction. The
conditions of ampliﬁcation reaction were as follow: 94 C for
3 min (initial denaturation); 94 C for 3 s (denaturation); 55 C
for 30 s (annealing); 72 C for 30 s (extension); 35 cycles; 72 C
for 5 min (extension); 4 C (conservation).
Five mL of PCR products were added in 2% agar gel and then
conducted to a horizontal electrophoresis for 30 min under a
condition of 100 V constant voltages. After that, the imaging
was observed by gel imaging system and a ﬂuorescent band
occurred in 440 bp was considered as the speciﬁc amplifying
products.
2.3.4. PCR-RFLP analysis
Enzyme reaction system: a total volume of materials was
25 mL within 10 mL PCR products, 2.5 mL 10 × buffer solution,
0.2 IU restriction endonuclease Eam1104I and 12.3 mL sterili-
zation deionized water. Reaction condition: a warm bath (37 C)
for 8 h was designed. Ten mL enzyme-digested products were
added into 2.0% agarose gel and then conducted to an electro-
phoresis for 30 min with 100 V constant voltages. The band was
observed in a gene genius bioimaging system and the experi-
ment results were photographed and recorded. Genotyping: a
restriction fragment [(150–440) bp] obtained after restriction
endonuclease reaction exhibited two kinds of polymorphism
allele (restriction fragment with 400 bp) and A allele (restriction
fragments with 150 bp and 290 bp). The PCR products obtained
in experiment were sent to the SBS Genetech Co., Ltd for
sequencing to conﬁrm the analysis results of restriction endo-
nuclease reaction.
2.3.5. Determination of blood lipid
The determination of blood lipid was carried out by using a
fully automatic biochemical analyzer conducted by Inspection
Center, the Sanya People's Hospital, Hainan.
2.4. Statistical analysis
The data analysis was carried out using statistical software
SPSS 21.0. chi-Square test was applied for the test of enumer-
ation data; t-test was used for the mean comparison of mea-
surement data between two groups; one-way analysis of
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groups. For calculation of gene frequency, the gene counting
method was utilized and chi-square test was also used for testing
results and the Hardy–Weinberg equilibrium was used for the
detection of representativeness of samples. P < 0.05 was
considered as statistically signiﬁcant.
3. Results
3.1. General conditions and serum lipid levels
The demographics (gender, age, region) in two groups
showed a good balance (P > 0.05) and there were no signiﬁcant
differences in the number of people smoking and drinking be-
tween two groups (P < 0.05). The levels of systolic pressure,
diastolic blood pressure, fasting blood sugar (FBS), triglyceride
(TG), total cholesterol (TC) and low density lipoprotein
cholesterol (LDL-C) of patients in CHD group were signiﬁcantly
higher than those in non-CHD group, while the high densityTable 1
Comparison of general conditions and serum lipid levels between CHD






Case (n) 233 239
Region
(Hainan/TPNC)
118/115 125/114 0.130 0.719
Gender
(male/female)
130/103 121/118 1.265 0.261








83.12 ± 10.15** 77.94 ± 6.72 6.511 0.000
Smoking
(Y/N) (n)
76/157 60/179 3.247 0.072
Drinking
(Y/N) (n)
44/189 61/178 3.006 0.083
FBS (mmol/L) 5.93 ± 1.12** 5.65 ± 0.47 3.558 0.000
TC (mmoL/L) 4.49 ± 0.75* 4.35 ± 0.75 2.075 0.039
TG (mmoL/L) 1.44 ± 0.81** 1.07 ± 0.45 6.148 0.000
HDL-C
(mmoL/L)
1.11 ± 0.37** 1.25 ± 0.31 −4.447 0.000
LDL-C
(mmoL/L)
2.86 ± 0.66* 2.74 ± 0.62 2.163 0.031
*: Compare to control group, P < 0.05; **: Compare to control group,
P < 0.01.
Table 2
Genetype distribution of CHD group and non-CHD group detected by Hard
Group Frequency Number of p
AA
CHD group Actual frequency 177 (76.0)
Theoretical frequency 173 (80.8)
Non-CHD group Actual frequency 215 (90.0)
Theoretical frequency 213 (93.8)lipoprotein cholesterol (HDL-C) level was lower than that in
non-CHD group (P < 0.05) (Table 1).
There were no signiﬁcant differences between actual geno-
type frequency and theoretical frequency of three genotypes in
CHD group and non-CHD group (P > 0.05), which showed the
allele frequency distribution was in accord with Hardy–Wein-
berg equilibrium (Table 2).
3.2. Dstribution of frequencies of three genotypes and
alleles in E670G of PCSK9 gene in CHD group and
non-CHD group
The frequencies of AG, GG genotypes in CHD group were
higher than those in non-CHD group (P < 0.01), and the fre-
quencies of G allele in CHD group were also higher than those
in non-CHD group (P < 0.01) (Table 3).
3.3. Comparison of frequencies of three genotypes and
alleles in E670G of PCSK9 gene between CHD groups
(Hainan and TPNC) and non-CHD groups (Hainan and
TPNC)
The gene frequencies of AG, GG genotypes and G allele in
Hainan CHD group were higher than those in Hainan non-CHD
group (P < 0.05), in TPNC, the gene frequencies of AG, GG
genotypes and G allele in CHD group were also higher than
those in non-CHD group (P < 0.01).
3.4. Comparison of frequencies of three genotypes and
allele of E670G polymorphism of PCSK9 gene
In CHD group, the frequencies of GG genotype and G allele
of patients with CHD in Hainan were both lower than that in
TPNC (P < 0.05), while in non-CHD group, the frequencies of
GG genotype and G allele between people in Hainan and TPNC
showed no signiﬁcant difference (P > 0.05) (Table 4).
3.5. Comparison between three genotypes of E670G
polymorphism in PCSK9 gene and serum lipid levels
In CHD group, the TG, TC and LDL-C levels of GG geno-
type were higher than those of AA genotype (P < 0.05).
Although the TG, TC, HDL-C and LDL-C levels between AG
and AA, GG and AG showed no signiﬁcant differences, the TG,
TC and LDL-C levels of patients carrying G allele were in a
gradually rising trend compared to those of patients with AA
genotype (Table 5).y–Weinberg equilibrium law.
eople with each genotype (n; %) c2 P value
AG GG
47 (20.2) 9 (3.8) 4.787 0.091
28 (13.1) 13 (6.1)
21 (8.8) 3 (1.2) 2.584 0.275
13 (5.7) 1 (0.4)
Table 3
Comparison of frequencies of three genotypes and alleles in E670G of the PCSK9 gene between CHD group and non-CHD group.
Group Case Number of people with each genetype (n; %) The number of people with each allele (n; %)
AA AG GG A G
CHD group 233 177 (76.0) 47 (20.2)** 9 (3.8)** 401 (86.1) 65 (13.9)**
Non-CHD group 239 215 (90.0) 21 (8.8) 3 (1.2) 451 (94.4) 27 (5.6)
c2 16.551 18.480
P value 0.000 0.000
**: Compare to non-CHD group, P < 0.01.
Table 4
Distribution of frequencies of three genotypes and allele of E670G polymorphism of PCSK9 gene in two group.
Group Region Case The number of people with each genotype (n;%) The number of people with each allele (n;%)
AA AG GG A G
Observation group Hainan 118 97 (82.2) 19 (16.1)* 2 (1.7)* 213 (90.3) 23 (9.7)**
TPNC 115 80 (69.6) 28 (24.3) 7 (6.1) 188 (81.7) 42 (18.3)
c2 6.096 7.036
P value 0.047 0.008
Control group Hainan 125 116 (92.8) 8 (6.4) 1 (0.8) 240 (96.0) 10 (4.0)
TPNC 114 99 (86.8) 13 (11.4) 2 (1.8) 211 (92.5) 17 (7.5)
c2 2.367 2.673
P value 0.306 0.102
*: Compare to TPNC patients with CHD in Observation group, P < 0.05; **: Compared to TPNC patients with CHD in Observation group, P < 0.01.
Table 5
Comparison of three genotypes of PCSK9 gene E670G polymorphism and serum lipid levels.
Serum lipid indexes Serum lipid level of various genotypes (mmoL/L) P value
AA (177) AG (47) GG (9) AA/AG AG/GG AA/GG
T C (mmoL/L) 4.44 ± 0.76 4.58 ± 0.67 5.10 ± 0.77 0.241 0.054 0.009
T G (mmoL/L) 1.40 ± 0.80 1.49 ± 0.89 1.95 ± 0.09 0.473 0.124 0.048
HDL-C (mmoL/L) 1.11 ± 0.38 1.14 ± 0.35 1.04 ± 0.24 0.591 0.451 0.586
LDL-C (mmoL/L) 2.84 ± 0.89 2.50 ± 0.59 3.30 ± 0.30 0.528 0.062 0.022
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The PCSK9 gene polymorphism is closely related to the
cardiovascular and cerebrovascular diseases during its occur-
rence, development and prognosis. PCSK9 gene mutations may
lead to a change in its normal function and thereby affecting the
expressions of a series of metabolite related to it. The PCSK9
gene polymorphism can result in the lipid metabolism disorder
and thus cause the hyperlipidemia which is closely related to the
occurrence and development of CHD [3]. CHD has a
characteristic of genetic predisposition with different morbidity
in distinct nationalities and regions. In population with the
same nationality from different areas, the genetic susceptibility
of CHD also shows signiﬁcant difference.
In the present study, the number of patients carrying G allele
in CHD group was higher than that in non-CHD group, and
either in population from Hainan or TPNC with the signiﬁcantly
statistical difference (P < 0.05). The study of Zeng conducted in
Sichuan region has revealed that G allele frequency of patients in
CHD group is higher than that in non-CHD group, which is
consistent with the results of this research [4]. And other present
studies have showed G allele frequency of patients with CHD in
Japan, the Caucasus, and Guangdong area in our country was
between 3.0% and 8.2%, which was lower than that in Africa
(26%–37.5%) [5–7]. Our study results revealed that the G allelefrequency of E670G in observation group was about
13.9%, also lower than that in Africa. To analyze its causes, it
may not only associate with the nationalities but also the
regions. Therefore, with consideration of region inﬂuence, a
comparative study on genotype frequency and allele frequency
was conducted in north area and south areas (Hainan, TPNC)
and the results showed that in control group (non-CHD), there
were no signiﬁcant differences in GG genotype and G allele
frequencies of people between Hainan and TPNC (P > 0.05),
while in observation group, GG genotype and G allele
frequencies of patients with CHD from Hainan were both
lower than those from TPNC, there were signiﬁcant
differences (P < 0.05). This result possibly correlates with the
differences of race, region and environmental condition. China
has vast territory, therefore geographical environment in its
north and south regions show differences and people also have
different living habits. Besides, affected by many external
factors and gene characteristics of people in different regions,
the gene polymorphisms of people in distinct areas or
nationalities would exhibit certain differences. From this
study, we also discovered a close correlation between E670G
polymorphisms and CHD, resulting different risks of CHD
occurrences.
PCSK9 gene can increase the risk of atherosclerosis by
effecting lipid metabolism. It plays a key role in adjusting the
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lysosomal degradation, decreasing the uptake of LDL-C and
therefore resulting in the increase of LDL-C, thus augmenting
the risk of getting CHD [8]. E670G polymorphism of PCSK9
gene is related to the plasma total cholesterol, apolipoprotein
and lipoprotein (A) level [9]. The research of Suet et al. has
revealed that the E670G mutation of PCSK9 gene is closely
related to the degree of coronary atherosclerosis and can be an
independent predictive factor for the increase of LDL-C level,
which up and down directly correlate with the risk of getting
CHD.
The genetic variation of PCSK9 gene greatly affects the
serum lipid level which expresses differently in various ge-
notypes. In the present study, the results showed that among
the patients with CHD, TG, TC, LDL-C levels of GG geno-
type were higher than those of AA genotype (P < 0.05).
Although the TG, TC, HDL-C and LDL-C levels between AG
and AA, GG and AG showed no signiﬁcant differences, the
TG, TC and LDL-C levels of patients carrying G allele were a
gradually rising trend compared to those of patients with AA
genotype. The studies of Zhang and Qiu showed that patients
carrying G allele had relatively higher levels of LDL-C, TG
and TC [10,11], and research by Aung et al. revealed E670G
polymorphism of PCSK9 gene was bound up with the
serum lipid level of Han population and among the people
with G allele, male expressed higher HDL-C, ApoA1 levels
[12]. Evans and Beil also found that carrying G allele of
PCSK9 gene E670G occurs in European men was related to
the signiﬁcant increase of LDL-C level, while this correla-
tion did not exist in women, which therefore revealed the
effects of E670G mutation of PCSK9 gene differ between
people in distinct regions or group. To analyze the cause
of this situation, it was found that a mutation occurred in
PCSK9 gene E670G affected the normal functions and thereby
inﬂuenced the lipid metabolism; different effects among
people in various regions or ethnic groups may caused by
their genes. Distinct ethnic backgrounds, living environments,
eating habits etc. would inﬂuence the synthesis and excretion
of it [13], which therefore resulted in the pathological
manifestations.
Many researches showed a close correlation between muta-
tion of PCSK9 gene and serum lipid level, the PCSK9 gene has
become a hot issue for the studies on the treatments of hyper-
lipidemia and CHD [14–16]. This research, by comparatively
studying the E670G polymorphism of PCSK9 gene of Han
population in different regions, revealed that there were
regional differences existed in E670G polymorphisms of
PCSK9 gene between patients with CHD in Hainan and TPNC
and the patients with distinct genotypes would exhibit
different serum lipid levels, which reminded us to pay
attention to the regional differences during the process of
prevention and treatment of hyperlipidemia and CHD. In the
future, we will investigate the exact mechanism which result
this difference and further discuss the correlation between
E670G polymorphism of the PCSK9 gene and abnormal lipid
metabolism, the occurrence and development of CHD as well
as the prognosis and its effects, therefore providing the
individualized theory basis for prevention and treatment of
CHD among population in distinct regions.Conﬂict of interest statement
We declare that we have no conﬂict of interest.
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